CC
EFTR

Callan Capital’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Callan Capital’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-800
Closed -$9.35K – 303
2023
Q4 		$9.35K Hold
800
– – ﹤0.01% 234
2023
Q3 		$12K Hold
800
– – ﹤0.01% 204
2023
Q2 		$16.6K Hold
800
– – ﹤0.01% 183
2023
Q1 		$7.05K Hold
800
– – ﹤0.01% 183
2022
Q4 		$8.55K Hold
800
– – ﹤0.01% 186
2022
Q3 		$11K Hold
800
– – ﹤0.01% 129
2022
Q2 		$28K Buy
+800
New +$48.4K ﹤0.01% 111

Other funds holding EFTR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Callan Capital's EFTR Position: Q1 2024 in Review

Callan Capital sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q1 2024, closing a stake of 800 shares — an estimated $9.35K sold.

Callan Capital first reported a position in EFTR in Q2 2022 and held it in 7 quarters. The position peaked at $28K in Q2 2022. 17 funds tracked by Wall St. Rank hold EFTR as of Q1 2024.

  • Callan Capital reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Callan Capital sold 800 eFFECTOR Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $9.35K.
  • Callan Capital first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q2 2022 and held it in 7 quarters.
  • Callan Capital's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $28K in Q2 2022.
  • 17 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Callan Capital's 13F filing for Q1 2024, filed 3 May 2024.